North American Prodromal Synucleinopathy Consortium Stage 2

Summary

This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

Conditions

• REM Sleep Behavior Disorder
• Parkinson Disease
• Lewy Body Dementia
• Dementia With Lewy Bodies
• Multiple System Atrophy
• REM Sleep Parasomnias

Sponsors & Collaborators

• Mayo Clinic

  collaborator OTHER

• University of Minnesota

  collaborator OTHER

• University of California, Los Angeles

  collaborator OTHER

• McGill University

  collaborator OTHER

• Emory University

  collaborator OTHER

• Massachusetts General Hospital

  collaborator OTHER

• National Institute of Neurological Disorders and Stroke (NINDS)

  collaborator NIH

• Stanford University

  collaborator OTHER

• National Institutes of Health (NIH)

  collaborator NIH

• Oregon Health and Science University

  collaborator OTHER

• National Institute on Aging (NIA)

  collaborator NIH

• Washington University School of Medicine

  lead OTHER

Principal Investigators

• Yo-El Ju, MD, MCSI · Washington University School of Medicine

• Brad Boeve, MD · Mayo Clinic

• Ron Postuma, MD · McGill University

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2022-08-12

Primary Completion

2027-05-01

Completion

2028-05-01

Countries

• United States
• Canada

Study Locations